BACKGROUND: Adherence of 95% or greater to highly active combination antiretroviral therapy is generally considered necessary to achieve optimal virologic suppression in HIV-infected patients. Understanding factors associated with poor adherence is essential to improve patient compliance, maximize virologic suppression, and reduce morbidity and mortality. METHODS: We evaluated baseline data from 528 patients taking antiretrovirals, enrolled from March 2004 to June 2006, in a multicenter, longitudinal, prospective cohort study (the SUN study). Using multiple logistic regression, we examined independent risk factors for non-adherence, defined as reporting having missed one or more antiretroviral doses in the past three days on the baseline questionnaire. RESULTS: Of 528 participants (22% female, 28% black, median age 41 years, and median CD4 cell count 486 cells/mm(3)), 85 (16%) were non-adherent. In the final parsimonious multivariate model, factors independently associated with non-adherence included black race (adjusted odds ratio (aOR): 2.08, 95% confidence interval (CI): 1.20-3.60 vs. white race), being unemployed and looking for work (aOR: 2.03, 95% CI: 1.14-3.61 vs. all other employment categories), having been diagnosed with HIV ≥5 years ago (aOR: 1.95, 95% CI: 1.18-3.24 vs. being HIV-diagnosed <5 years ago), drinking three or more drinks per day (aOR: 1.73, 95% CI: 1.02-2.91 vs. drinking <3 drinks per day), and having not engaged in any aerobic exercise in the last 30 days (aOR: 2.13, 95% CI: 1.25-3.57). CONCLUSION: Although the above factors may not be causally related to non-adherence, they might serve as proxies for identifying HIV-infected patients at greatest risk for non-adherence who may benefit from additional adherence support.
BACKGROUND: Adherence of 95% or greater to highly active combination antiretroviral therapy is generally considered necessary to achieve optimal virologic suppression in HIV-infectedpatients. Understanding factors associated with poor adherence is essential to improve patient compliance, maximize virologic suppression, and reduce morbidity and mortality. METHODS: We evaluated baseline data from 528 patients taking antiretrovirals, enrolled from March 2004 to June 2006, in a multicenter, longitudinal, prospective cohort study (the SUN study). Using multiple logistic regression, we examined independent risk factors for non-adherence, defined as reporting having missed one or more antiretroviral doses in the past three days on the baseline questionnaire. RESULTS: Of 528 participants (22% female, 28% black, median age 41 years, and median CD4 cell count 486 cells/mm(3)), 85 (16%) were non-adherent. In the final parsimonious multivariate model, factors independently associated with non-adherence included black race (adjusted odds ratio (aOR): 2.08, 95% confidence interval (CI): 1.20-3.60 vs. white race), being unemployed and looking for work (aOR: 2.03, 95% CI: 1.14-3.61 vs. all other employment categories), having been diagnosed with HIV ≥5 years ago (aOR: 1.95, 95% CI: 1.18-3.24 vs. being HIV-diagnosed <5 years ago), drinking three or more drinks per day (aOR: 1.73, 95% CI: 1.02-2.91 vs. drinking <3 drinks per day), and having not engaged in any aerobic exercise in the last 30 days (aOR: 2.13, 95% CI: 1.25-3.57). CONCLUSION: Although the above factors may not be causally related to non-adherence, they might serve as proxies for identifying HIV-infectedpatients at greatest risk for non-adherence who may benefit from additional adherence support.
Authors: Jennifer G Okonsky; Allison Webel; Carol Dawson Rose; Mallory Johnson; Alice Asher; Yvette Cuca; Alphoncina Kaihura; Jan E Hanson; Carmen J Portillo Journal: Health Care Women Int Date: 2014-05-15
Authors: Hong-Van Tieu; Beryl A Koblin; Carl Latkin; Frank C Curriero; Emily R Greene; Andrew Rundle; Victoria Frye Journal: J Urban Health Date: 2020-10 Impact factor: 3.671
Authors: Cathy M Puskas; Jamie I Forrest; Surita Parashar; Kate A Salters; Angela M Cescon; Angela Kaida; Cari L Miller; David R Bangsberg; Robert S Hogg Journal: Curr HIV/AIDS Rep Date: 2011-12 Impact factor: 5.071
Authors: Marya Gwadz; Charles M Cleland; Mindy Belkin; Amanda Ritchie; Noelle Leonard; Marion Riedel; Angela Banfield; Pablo Colon; Vanessa Elharrar; Jonathan Kagan; Donna Mildvan Journal: AIDS Behav Date: 2014-12
Authors: Rupali Kotwal Doshi; Nicholas S Vogenthaler; Sarah Lewis; Allan Rodriguez; Lisa Metsch; Carlos del Rio Journal: AIDS Res Hum Retroviruses Date: 2012-03-02 Impact factor: 2.205
Authors: Luwam Ghidei; Mark J Simone; Marci J Salow; Kristin M Zimmerman; Allison M Paquin; Lara M Skarf; Tia R M Kostas; James L Rudolph Journal: Drugs Aging Date: 2013-10 Impact factor: 3.923
Authors: M Barton Laws; Yoojin Lee; William H Rogers; Mary Catherine Beach; Somnath Saha; P Todd Korthuis; Victoria Sharp; Jonathan Cohn; Richard Moore; Ira B Wilson Journal: AIDS Behav Date: 2014-07
Authors: Anandi N Sheth; Ighovwerha Ofotokun; Kate Buchacz; Carl Armon; Joan S Chmiel; Rachel L D Hart; Rose Baker; John T Brooks; Frank J Palella Journal: J Acquir Immune Defic Syndr Date: 2016-01-01 Impact factor: 3.731